Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors.
Authors:
Journal: Expert opinion on pharmacotherapy
Publication Type: Journal Article
Date: 2011
DOI: 10.1517/14656566.2011.600306
ID: 21774742
Abstract
At the present time, inhibitors of phosphodiesterase type 5 (PDE5) have Food and Drug Administration approval only for the treatment of erectile dysfunction and pulmonary artery hypertension, for which their mechanism of action is vasodilation and augmentation of blood flow by impeding PDE5-mediated breakdown of cyclic guanosine monophosphate. However, these agents are also being investigated in a wide range of other potential medical and surgical applications for which current treatment options are limited and in which their mechanism of action may be the same as or different from their effects in the two approved indications. Even if only some of these potential applications prove useful, the effect on clinical practice could be far reaching.
Chemical List
- Phosphodiesterase 5 Inhibitors